fluconazole has been researched along with Leukemia in 58 studies
Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.
fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.
Leukemia: A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)
| Excerpt | Relevance | Reference |
|---|---|---|
| " We performed a randomized trial to compare itraconazole vs fluconazole, for prevention of IFIs in patients with acute leukemia (AL) and HSCT recipients." | 9.12 | A prospective randomized trial of itraconazole vs fluconazole for the prevention of fungal infections in patients with acute leukemia and hematopoietic stem cell transplant recipients. ( Akria, L; Benyamini, N; Dally, N; Dann, EJ; Fineman, R; Gorelik, A; Haddad, N; Oren, I; Rowe, JM; Sprecher, H; Tamir, A; Zuckerman, T, 2006) |
| "A pilot exploratory study was undertaken to collect preliminary information relating to safety and overall outcome in using intravenous fluconazole (FLUC) for managing antibiotic resistant neutropenic fever (ARNF), with the objective of assessing feasibility of performing a larger prospective controlled study." | 9.08 | Systemic amphotericin B versus fluconazole in the management of antibiotic resistant neutropenic fever--preliminary observations from a pilot, exploratory study. ( Baillie, F; Clink, H; Ellis, ME; Ernst, P; Greer, W; Halim, MA; Kalin, M; Spence, D, 1995) |
| "Fluconazole was at least as effective as oral amphotericin B in preventing systemic and superficial fungal infection and the empiric use of amphotericin B in neutropenic patients with acute leukemia but was better tolerated." | 9.07 | Preventing fungal infection in neutropenic patients with acute leukemia: fluconazole compared with oral amphotericin B. ( Barbui, T; Bucaneve, G; Carotenuto, M; D'Antonio, D; Del Favero, A; Fasola, G; Liso, V; Mandelli, F; Martino, P; Menichetti, F; Micozzi, A; Nosari, AM; Ricci, P, 1994) |
| "Prophylactic fluconazole prevents colonization and superficial infections by Candida species other than Candida krusei in patients undergoing chemotherapy for acute leukemia and is well tolerated." | 9.07 | Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial. ( Buell, DN; Chandrasekar, PH; Goodman, JL; Ho, WG; Horowitz, H; Islam, MZ; Lazarus, HM; Rosenfeld, CS; Shadduck, RK; Silber, JL; Winston, DJ, 1993) |
| "Medical records of 154 children with acute leukemia who received AFP with fluconazole during intensive chemotherapy were retrospectively reviewed to determine risk factors, clinical characteristics and outcome of IFI." | 7.75 | Invasive fungal infections in pediatric leukemia patients receiving fluconazole prophylaxis. ( Albayrak, M; Aral, YZ; Gursel, T; Kalkanci, A; Kaya, Z; Kocak, U, 2009) |
| "The efficacy of fluconazole prophylaxis to prevent invasive candida infections in patients with acute leukaemia receiving chemotherapy is not clear." | 7.74 | Effect of fluconazole prophylaxis on the incidence of invasive candida infections and bacteraemias in patients with acute leukaemia. ( Anttila, VJ; Elonen, E; Juvonen, E; Nihtinen, A; Ruutu, T; Volin, L, 2008) |
| "Six patients (ages 3 to 44) with acute leukemia and hepatosplenic candidiasis who did not respond to prior antifungal therapy were treated with fluconazole." | 7.68 | Hepatosplenic candidiasis: successful treatment with fluconazole. ( Bradley, SF; Kauffman, CA; Ross, SC; Weber, DR, 1991) |
| "The clinical efficacy of fluconazole at doses of 100-400 mg daily given intravenously in the treatment of 6 cases of deep mycosis complicated with leukemia was evaluated." | 7.67 | [Clinical evaluation of fluconazole in the case of deep mycosis associated with leukemia]. ( Fukawa, H; Kodama, F; Maruta, A; Matsuzaki, M, 1989) |
| "Disseminated candidiasis is a serious infectious complication with a mortality as high as 50%." | 6.68 | An open study on the safety and efficacy of fluconazole in the treatment of disseminated Candida infections in patients treated for hematological malignancy. ( de Pauw, BE; Donnelly, JP; Kullberg, BJ; Meis, JF; Raemaekers, JM, 1995) |
| "Fluconazole (FLU) is a new antifungal agent that has been used successfully to treat Candida infections and has modest activity against aspergillosis in animal models." | 6.67 | Antifungal prophylaxis during remission induction therapy for acute leukemia fluconazole versus intravenous amphotericin B. ( Anaissie, EJ; Bodey, GP; Elting, LS; Estey, E; Kantarjian, H; O'Brien, S, 1994) |
| " We performed a randomized trial to compare itraconazole vs fluconazole, for prevention of IFIs in patients with acute leukemia (AL) and HSCT recipients." | 5.12 | A prospective randomized trial of itraconazole vs fluconazole for the prevention of fungal infections in patients with acute leukemia and hematopoietic stem cell transplant recipients. ( Akria, L; Benyamini, N; Dally, N; Dann, EJ; Fineman, R; Gorelik, A; Haddad, N; Oren, I; Rowe, JM; Sprecher, H; Tamir, A; Zuckerman, T, 2006) |
| "A pilot exploratory study was undertaken to collect preliminary information relating to safety and overall outcome in using intravenous fluconazole (FLUC) for managing antibiotic resistant neutropenic fever (ARNF), with the objective of assessing feasibility of performing a larger prospective controlled study." | 5.08 | Systemic amphotericin B versus fluconazole in the management of antibiotic resistant neutropenic fever--preliminary observations from a pilot, exploratory study. ( Baillie, F; Clink, H; Ellis, ME; Ernst, P; Greer, W; Halim, MA; Kalin, M; Spence, D, 1995) |
| "To evaluate efficacy of ampicilline/sulbactame and fluconasole in the regimen of empirical antibiotic therapy in patients with acute leukemia." | 5.08 | [The empirical antibiotic therapy of patients with acute leukemias: the results of a multicenter study]. ( Filatov, LB; Iarikova, EN; Isaev, VG; Kaletin, GI; Kaporskaia, TS; Kliasova, GA; Klimko, NN; Lapin, VA; Medvedeva, NV; Parovichnikova, EN; Porokhona, ON; Pristupa, AS; Rekhtman, GB; Rossiev, VA; Savchenko, VG; Sharov, LN; Tolkacheva, TV; Tumakov, VA, 1998) |
| "Fluconazole was at least as effective as oral amphotericin B in preventing systemic and superficial fungal infection and the empiric use of amphotericin B in neutropenic patients with acute leukemia but was better tolerated." | 5.07 | Preventing fungal infection in neutropenic patients with acute leukemia: fluconazole compared with oral amphotericin B. ( Barbui, T; Bucaneve, G; Carotenuto, M; D'Antonio, D; Del Favero, A; Fasola, G; Liso, V; Mandelli, F; Martino, P; Menichetti, F; Micozzi, A; Nosari, AM; Ricci, P, 1994) |
| "Prophylactic fluconazole prevents colonization and superficial infections by Candida species other than Candida krusei in patients undergoing chemotherapy for acute leukemia and is well tolerated." | 5.07 | Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial. ( Buell, DN; Chandrasekar, PH; Goodman, JL; Ho, WG; Horowitz, H; Islam, MZ; Lazarus, HM; Rosenfeld, CS; Shadduck, RK; Silber, JL; Winston, DJ, 1993) |
| "Efficacies of fluconazole (FLCZ) were evaluated in 8 cases of systemic mycosis (1 case each of candidemia, candiduria, 4 cases of pulmonary candidiasis, and 2 cases of suspected fungemia) complicated in immunocompromised children." | 5.07 | [A clinical study of fluconazole in the treatment of systemic mycosis associated with immunocompromised children]. ( Hatae, Y; Ishikawa, A; Ishikawa, Y; Matsumoto, S; Sakiyama, Y; Shimizu, T; Takase, A; Takeda, T; Wagatsuma, Y, 1994) |
| "The efficacy and safety of oral fluconazole versus a polyene regimen in preventing mycoses in neutropenic patients was compared." | 5.07 | Controlled study of fluconazole in the prevention of fungal infections in neutropenic patients with haematological malignancies and bone marrow transplant recipients. ( Burnie, J; Clink, H; Ellis, ME; Ernst, P; Greer, W; Halim, MA; Hussain Qadri, SM; Kalin, M; Padmos, A; Spence, D, 1994) |
| " Our study was designed to assess the prevention of (1) staphylococcal and streptococcal infections using T when the central catheter is being placed, and (2) candida infection by the simultaneous use of a new anti-mycotic agent fluconazole (F) administered once-daily." | 5.06 | Prevention of gram-positive and Candida albicans infections using teicoplanin and fluconazole: a randomized study in neutropenic children. ( Arlet, G; Baruchel, A; Schaison, G, 1990) |
| "Forty patients with acute leukemia (age 16-71 years, 13 females, 27 males) with induced neutropenia due to chemotherapy received either 50 mg fluconazole or 800 mg amphotericin B per day orally as prophylaxis against fungal infection." | 5.06 | [Comparison of oral fluconazole and amphotericin B prophylaxis against fungal infections in the neutropenic phase of patients treated with antileukemic agents]. ( Finke, R, 1990) |
| "Medical records of 154 children with acute leukemia who received AFP with fluconazole during intensive chemotherapy were retrospectively reviewed to determine risk factors, clinical characteristics and outcome of IFI." | 3.75 | Invasive fungal infections in pediatric leukemia patients receiving fluconazole prophylaxis. ( Albayrak, M; Aral, YZ; Gursel, T; Kalkanci, A; Kaya, Z; Kocak, U, 2009) |
| "The efficacy of fluconazole prophylaxis to prevent invasive candida infections in patients with acute leukaemia receiving chemotherapy is not clear." | 3.74 | Effect of fluconazole prophylaxis on the incidence of invasive candida infections and bacteraemias in patients with acute leukaemia. ( Anttila, VJ; Elonen, E; Juvonen, E; Nihtinen, A; Ruutu, T; Volin, L, 2008) |
| "Candida krusei is a cause of invasive candidiasis (IC), with numerous cases reported among leukemia patients after bone marrow transplantation and treatment with fluconazole." | 3.69 | Invasive infection due to Candida krusei in immunocompromised patients not treated with fluconazole. ( Hinrichs, SH; Iwen, PC; Kelly, DM; Reed, EC, 1995) |
| "Efficacy of fluconazole (FLCZ), an anti-fungal agent of triazole derivatives, was evaluated in patients with systemic mycoses and suspected mycoses associated with hematologic malignancies including leukemia, myelodysplastic syndrome and malignant lymphoma." | 3.68 | [Efficacy of fluconazole on systemic mycosis associated with hematologic malignancies and a study on diagnostic value of plasma beta-D-glucan levels]. ( Hirakawa, K; Horiike, S; Kashima, K; Kuzuyama, Y; Misawa, S; Nakai, H; Seryu, T; Takashima, T; Taniwaki, M; Tsuda, S, 1993) |
| "Six patients (ages 3 to 44) with acute leukemia and hepatosplenic candidiasis who did not respond to prior antifungal therapy were treated with fluconazole." | 3.68 | Hepatosplenic candidiasis: successful treatment with fluconazole. ( Bradley, SF; Kauffman, CA; Ross, SC; Weber, DR, 1991) |
| "The clinical efficacy of fluconazole at doses of 100-400 mg daily given intravenously in the treatment of 6 cases of deep mycosis complicated with leukemia was evaluated." | 3.67 | [Clinical evaluation of fluconazole in the case of deep mycosis associated with leukemia]. ( Fukawa, H; Kodama, F; Maruta, A; Matsuzaki, M, 1989) |
| "Disseminated candidiasis is a serious infectious complication with a mortality as high as 50%." | 2.68 | An open study on the safety and efficacy of fluconazole in the treatment of disseminated Candida infections in patients treated for hematological malignancy. ( de Pauw, BE; Donnelly, JP; Kullberg, BJ; Meis, JF; Raemaekers, JM, 1995) |
| "Fungal infections are a major problem in patients with hematologic malignancy." | 2.68 | Effect of prophylactic fluconazole on the frequency of fungal infections, amphotericin B use, and health care costs in patients undergoing intensive chemotherapy for hematologic neoplasias. ( Schaffner, A; Schaffner, M, 1995) |
| "Fluconazole was particularly effective in reducing the carriage of C." | 2.67 | The effect of fluconazole prophylaxis on fungal colonization in neutropenic cancer patients. Bone Marrow Transplantation Team. ( Chandrasekar, PH; Gatny, CM, 1994) |
| "Fluconazole (FLU) is a new antifungal agent that has been used successfully to treat Candida infections and has modest activity against aspergillosis in animal models." | 2.67 | Antifungal prophylaxis during remission induction therapy for acute leukemia fluconazole versus intravenous amphotericin B. ( Anaissie, EJ; Bodey, GP; Elting, LS; Estey, E; Kantarjian, H; O'Brien, S, 1994) |
| "Systemic fungal infections were documented in 48 patients and suspected in 61 patients." | 2.67 | [Clinical study of fluconazole for systemic fungal infections with hematological disorders]. ( Aoki, I; Kitamura, S; Miyakawa, K; Ohbayashi, Y; Sato, H; Shindo, E; Takaku, F; Togawa, A; Urabe, A; Wakabayashi, Y, 1993) |
| "05; ANOVA) in the pharmacokinetic parameters of fluconazole (AUC, Cmax, Tmax) were found during the three days of the trial." | 2.67 | Administration of the antimycotic agents fluconazole and itraconazole to leukaemia patients: a comparative pharmacokinetic study. ( Lazo de la Vega, S; Pfaff, G; Volkow, P; Yeates, RA, 1994) |
| "Two different flucytosine (5-FC) treatment regimens, one by itself and the other in combination with fluconazole (FLCZ) were compared in chemotherapy against mycotic infections in 60 patients with hematological diseases." | 2.67 | [A comparative clinical study on flucytosine alone and in combination with fluconazole in hematological malignancies: a multicenter study using the envelope method]. ( Ariyoshi, H; Hamajima, N; Hotta, T; Kodera, Y; Murate, T; Naito, K; Naoe, T; Ogura, M; Saito, H; Tanaka, M, 1994) |
| "Fluconazole was as effective as amphotericin B in preventing severe local and disseminated fungal disease (one documented and one highly suspected infection in each group of patients)." | 2.67 | A randomized study to compare oral fluconazole to amphotericin B in the prevention of fungal infections in patients with acute leukaemia. ( Branger, J; Dekker, AW; Rozenberg-Arska, M; Verhoef, J, 1991) |
| "Over a 12 year period 19 children treated for leukemia at our institution developed C." | 2.38 | Candida tropicalis infections in children with leukemia. ( Flynn, PM; Hughes, WT; Marina, NM; Rivera, GK, 1993) |
| " Liposomal Amphotericin B allowing higher dosage by lower toxicity appears effective as salvage treatment especially in aspergillosis which also responds to Itraconazole available as oral formulation so far." | 2.38 | Antifungal treatment strategy in leukemia patients. ( Büchner, T; Roos, N, 1992) |
| "We describe drug-drug interactions (DDIs) encountered with antifungals in clinical practice." | 1.34 | Drug-drug interactions with systemic antifungals in clinical practice. ( Abouelfath, A; Depont, F; Dupon, M; Dutronc, H; Galpérine, T; Giauque, E; Hébert, G; Moore, N; Ragnaud, JM; Valentino, R; Vargas, F, 2007) |
| "The sinusitis was successfully treated with AmBisome, and surgical debridement." | 1.33 | Zygomycosis in the immunocompromised patient: a case report. ( Aoun, M; Beguin, H; Georgala, A; Husson, M; Meuleman, N; Nolard, N; Vekemans, M, 2006) |
| "Fluconazole is considered to be a potent, safe antifungal agent for the treatment of suspected fungal infections associated with hematological diseases." | 1.29 | [Clinical efficacy of fluconazole against fungal infections in hematological diseases]. ( Asahara, F; Hisano, S; Kawasaki, C; Kimura, N; Morioka, E; Nagano, M; Nakashima, H; Okumura, M; Suzumiya, J; Uchida, T; Yoshida, T, 1996) |
| "Fluconazole (FLCZ) was administrated 100-400 mg/day intravenously or orally to 79 patients with systemic fungal infections complicated with hematological disorders and it was possible to evaluate clinical efficacies in 60 patients." | 1.29 | [A clinical evaluation of fluconazole in deep seated fungal infections associated with hematological disorders]. ( Asano, Y; Eto, S; Ikeda, K; Izumi, Y; Misago, M; Mori, N; Morimoto, I; Murakami, S; Nagata, K; Nakanishi, M; Nakata, K; Oda, E; Oda, S; Ogawa, R; Ohkuma, K; Ohmori, F; Ohnishi, Y; Sawada, H; Tanaka, H; Tohnai, S; Tsukada, J; Wake, A; Yamamura, M; Yamano, Y; Yamasaki, Y, 1996) |
| " No significant adverse reactions nor abnormality in clinical laboratory tests related with the dosing of fluconazole were observed in any of the patients." | 1.28 | [A clinical evaluation of injectable fluconazole in the treatment of deep mycosis associated with hematological malignancy]. ( Hojo, H; Lin, KY; Torii, Y; Toyama, K; Tsuda, A; Yoshikawa, O, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (3.45) | 18.7374 |
| 1990's | 37 (63.79) | 18.2507 |
| 2000's | 13 (22.41) | 29.6817 |
| 2010's | 5 (8.62) | 24.3611 |
| 2020's | 1 (1.72) | 2.80 |
| Authors | Studies |
|---|---|
| Meryk, A | 1 |
| Kropshofer, G | 1 |
| Hutter, J | 1 |
| Fritz, J | 1 |
| Salvador, C | 1 |
| Lass-Flörl, C | 1 |
| Crazzolara, R | 1 |
| Fukuda, T | 1 |
| Brissot, E | 1 |
| Cahu, X | 1 |
| Guillaume, T | 1 |
| Delaunay, J | 1 |
| Ayari, S | 1 |
| Peterlin, P | 1 |
| Le Bourgeois, A | 1 |
| Harousseau, JL | 1 |
| Milpied, N | 1 |
| Bene, MC | 1 |
| Moreau, P | 1 |
| Mohty, M | 1 |
| Chevallier, P | 1 |
| Fernández-Ruiz, M | 1 |
| Puig-Asensio, M | 1 |
| Guinea, J | 1 |
| Almirante, B | 1 |
| Padilla, B | 1 |
| Almela, M | 1 |
| Díaz-Martín, A | 1 |
| Rodríguez-Baño, J | 1 |
| Cuenca-Estrella, M | 1 |
| Aguado, JM | 1 |
| Heidenreich, D | 1 |
| Kreil, S | 1 |
| Nolte, F | 1 |
| Reinwald, M | 1 |
| Hofmann, WK | 1 |
| Klein, SA | 1 |
| Kaya, Z | 1 |
| Gursel, T | 1 |
| Kocak, U | 1 |
| Aral, YZ | 1 |
| Kalkanci, A | 1 |
| Albayrak, M | 1 |
| Savini, V | 1 |
| Hendrickx, M | 1 |
| Sisti, M | 1 |
| Masciarelli, G | 1 |
| Favaro, M | 1 |
| Fontana, C | 1 |
| Pitzurra, L | 1 |
| Arzeni, D | 1 |
| Astolfi, D | 1 |
| Catavitello, C | 1 |
| Polilli, E | 1 |
| Farina, C | 1 |
| Fazii, P | 1 |
| D'Antonio, D | 2 |
| Stubbe, D | 1 |
| Myoken, Y | 3 |
| Kyo, T | 2 |
| Kohara, T | 1 |
| Fujihara, M | 2 |
| Sugata, T | 2 |
| Mikami, Y | 2 |
| Menichetti, F | 2 |
| O'Neill, JT | 1 |
| Blair, M | 1 |
| Graham, BS | 1 |
| Alexander, BD | 1 |
| Schell, WA | 1 |
| Miller, JL | 1 |
| Long, GD | 1 |
| Perfect, JR | 1 |
| Halliday, C | 1 |
| Hoile, R | 1 |
| Sorrell, T | 1 |
| James, G | 1 |
| Yadav, S | 1 |
| Shaw, P | 1 |
| Bleakley, M | 1 |
| Bradstock, K | 1 |
| Chen, S | 1 |
| Oren, I | 1 |
| Rowe, JM | 1 |
| Sprecher, H | 1 |
| Tamir, A | 1 |
| Benyamini, N | 1 |
| Akria, L | 1 |
| Gorelik, A | 1 |
| Dally, N | 1 |
| Zuckerman, T | 1 |
| Haddad, N | 1 |
| Fineman, R | 1 |
| Dann, EJ | 1 |
| Georgala, A | 1 |
| Vekemans, M | 1 |
| Husson, M | 1 |
| Meuleman, N | 1 |
| Beguin, H | 1 |
| Nolard, N | 1 |
| Aoun, M | 1 |
| Kennedy, HF | 1 |
| Shankland, GS | 1 |
| Bagg, J | 1 |
| Chalmers, EA | 1 |
| Gibson, BE | 1 |
| Williams, CL | 1 |
| Depont, F | 1 |
| Vargas, F | 1 |
| Dutronc, H | 1 |
| Giauque, E | 1 |
| Ragnaud, JM | 1 |
| Galpérine, T | 1 |
| Abouelfath, A | 1 |
| Valentino, R | 1 |
| Dupon, M | 1 |
| Hébert, G | 1 |
| Moore, N | 1 |
| Nihtinen, A | 1 |
| Anttila, VJ | 1 |
| Elonen, E | 1 |
| Juvonen, E | 1 |
| Volin, L | 1 |
| Ruutu, T | 1 |
| Schaffner, A | 1 |
| Schaffner, M | 1 |
| Ellis, ME | 2 |
| Halim, MA | 2 |
| Spence, D | 3 |
| Ernst, P | 3 |
| Clink, H | 2 |
| Kalin, M | 2 |
| Baillie, F | 1 |
| Greer, W | 2 |
| Iwen, PC | 1 |
| Kelly, DM | 1 |
| Reed, EC | 1 |
| Hinrichs, SH | 1 |
| Naito, K | 1 |
| Murate, T | 1 |
| Hotta, T | 1 |
| Saito, H | 1 |
| Hamajima, N | 1 |
| Naoe, T | 1 |
| Ogura, M | 1 |
| Ariyoshi, H | 1 |
| Tanaka, M | 1 |
| Kodera, Y | 1 |
| de Pauw, BE | 1 |
| Raemaekers, JM | 1 |
| Donnelly, JP | 1 |
| Kullberg, BJ | 1 |
| Meis, JF | 1 |
| Lazo de la Vega, S | 1 |
| Volkow, P | 1 |
| Yeates, RA | 1 |
| Pfaff, G | 1 |
| Fukuda, M | 1 |
| Hirashima, K | 1 |
| Kurane, R | 1 |
| Abe, T | 1 |
| Sampi, K | 1 |
| Tominaga, K | 1 |
| Tsuji, M | 1 |
| Takagi, S | 1 |
| Naito, T | 1 |
| Chubachi, A | 2 |
| Miura, I | 2 |
| Ohshima, A | 2 |
| Nishinari, T | 1 |
| Nimura, T | 2 |
| Niitsu, H | 2 |
| Miura, AB | 2 |
| Bodey, GP | 1 |
| Anaissie, EJ | 1 |
| Elting, LS | 1 |
| Estey, E | 1 |
| O'Brien, S | 1 |
| Kantarjian, H | 1 |
| Padmos, A | 1 |
| Hussain Qadri, SM | 1 |
| Burnie, J | 1 |
| Del Favero, A | 1 |
| Martino, P | 2 |
| Bucaneve, G | 1 |
| Micozzi, A | 1 |
| Ricci, P | 1 |
| Carotenuto, M | 1 |
| Liso, V | 1 |
| Nosari, AM | 1 |
| Barbui, T | 1 |
| Fasola, G | 1 |
| Mandelli, F | 1 |
| Akiyama, H | 2 |
| Mori, S | 1 |
| Tanikawa, S | 1 |
| Sakamaki, H | 2 |
| Onozawa, Y | 2 |
| Chandrasekar, PH | 2 |
| Gatny, CM | 1 |
| Ishikawa, Y | 1 |
| Shimizu, T | 1 |
| Sakiyama, Y | 1 |
| Matsumoto, S | 1 |
| Hatae, Y | 1 |
| Takeda, T | 1 |
| Ishikawa, A | 1 |
| Takase, A | 1 |
| Wagatsuma, Y | 1 |
| Kliasova, GA | 2 |
| Pavia, AT | 1 |
| Riley, DK | 1 |
| Flynn, PM | 1 |
| Marina, NM | 1 |
| Rivera, GK | 1 |
| Hughes, WT | 1 |
| Wingard, JR | 2 |
| Merz, WG | 2 |
| Rinaldi, MG | 2 |
| Miller, CB | 1 |
| Karp, JE | 2 |
| Saral, R | 2 |
| Tsuda, S | 1 |
| Misawa, S | 1 |
| Horiike, S | 1 |
| Hirakawa, K | 1 |
| Kuzuyama, Y | 1 |
| Nakai, H | 1 |
| Seryu, T | 1 |
| Takashima, T | 1 |
| Taniwaki, M | 1 |
| Kashima, K | 1 |
| Kitamura, S | 1 |
| Miyakawa, K | 1 |
| Wakabayashi, Y | 1 |
| Urabe, A | 1 |
| Sato, H | 1 |
| Ohbayashi, Y | 1 |
| Takaku, F | 1 |
| Togawa, A | 1 |
| Shindo, E | 1 |
| Aoki, I | 1 |
| Winston, DJ | 1 |
| Lazarus, HM | 1 |
| Goodman, JL | 1 |
| Silber, JL | 1 |
| Horowitz, H | 1 |
| Shadduck, RK | 1 |
| Rosenfeld, CS | 1 |
| Ho, WG | 1 |
| Islam, MZ | 1 |
| Buell, DN | 1 |
| Girmenia, C | 1 |
| Cassone, A | 1 |
| Morioka, E | 1 |
| Asahara, F | 1 |
| Nagano, M | 1 |
| Kawasaki, C | 1 |
| Yoshida, T | 1 |
| Uchida, T | 1 |
| Nakashima, H | 1 |
| Suzumiya, J | 1 |
| Kimura, N | 1 |
| Hisano, S | 1 |
| Okumura, M | 1 |
| Murakami, S | 1 |
| Misago, M | 1 |
| Tohnai, S | 1 |
| Nakanishi, M | 1 |
| Ogawa, R | 1 |
| Wake, A | 1 |
| Nagata, K | 1 |
| Mori, N | 1 |
| Tsukada, J | 1 |
| Nakata, K | 1 |
| Oda, S | 1 |
| Morimoto, I | 1 |
| Eto, S | 1 |
| Izumi, Y | 1 |
| Sawada, H | 1 |
| Yamasaki, Y | 1 |
| Yamano, Y | 1 |
| Ohmori, F | 1 |
| Ohkuma, K | 1 |
| Ohnishi, Y | 1 |
| Yamamura, M | 1 |
| Asano, Y | 1 |
| Tanaka, H | 1 |
| Ikeda, K | 1 |
| Oda, E | 1 |
| El-Yazigi, A | 1 |
| Ellis, M | 1 |
| Hussain, R | 1 |
| Baillie, FJ | 1 |
| Savchenko, VG | 1 |
| Parovichnikova, EN | 1 |
| Isaev, VG | 1 |
| Tolkacheva, TV | 1 |
| Rossiev, VA | 1 |
| Filatov, LB | 1 |
| Tumakov, VA | 1 |
| Iarikova, EN | 1 |
| Rekhtman, GB | 1 |
| Pristupa, AS | 1 |
| Medvedeva, NV | 1 |
| Sharov, LN | 1 |
| Klimko, NN | 1 |
| Porokhona, ON | 1 |
| Lapin, VA | 1 |
| Kaporskaia, TS | 1 |
| Kaletin, GI | 1 |
| Young, GA | 1 |
| Bosly, A | 1 |
| Gibbs, DL | 1 |
| Durrant, S | 1 |
| Peggs, KS | 1 |
| Preiser, W | 1 |
| Kottaridis, PD | 1 |
| McKeag, N | 1 |
| Brink, NS | 1 |
| Tedder, RS | 1 |
| Goldstone, AH | 1 |
| Linch, DC | 1 |
| Mackinnon, S | 1 |
| Segal, RE | 1 |
| Minamoto, GY | 1 |
| Büchner, T | 1 |
| Roos, N | 1 |
| Johnson, TR | 1 |
| Kauffman, CA | 1 |
| Bradley, SF | 1 |
| Ross, SC | 1 |
| Weber, DR | 1 |
| Rozenberg-Arska, M | 1 |
| Dekker, AW | 1 |
| Branger, J | 1 |
| Verhoef, J | 1 |
| De Beule, F | 1 |
| Bercy, P | 1 |
| Ferrant, A | 1 |
| Finke, R | 1 |
| Schaison, G | 1 |
| Baruchel, A | 1 |
| Arlet, G | 1 |
| Maruta, A | 1 |
| Matsuzaki, M | 1 |
| Fukawa, H | 1 |
| Kodama, F | 1 |
| Toyama, K | 1 |
| Lin, KY | 1 |
| Hojo, H | 1 |
| Tsuda, A | 1 |
| Torii, Y | 1 |
| Yoshikawa, O | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Trial to Evaluate the Safety and Tolerability of Nebulised Amphotericin B Lipid Complex (ABELCET®) in the Prophylaxis of Invasive Pulmonary Aspergillosis During Prolonged Neutropenia in Paediatric Patients With Acute Leukaemia[NCT01615809] | Phase 2 | 32 participants (Actual) | Interventional | 2011-10-31 | Completed | ||
| ANTIVORIFUNGOL:Strategy of Antifungal Use in Oncohematological Neutropenic Patients. Use of Voriconazole as Early Treatment.[NCT00386802] | Phase 4 | 115 participants (Anticipated) | Interventional | 2006-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The incidence of invasive pulmonary aspergillosis during the Abelcet® prophylactic treatment period was assessed by the relation between the number of patients with invasive pulmonary aspergillosis and the number of paediatric patients on prophylaxis with Acute Leukaemia (AL) undergoing intensive chemotherapy. (NCT01615809)
Timeframe: at the Baseline visit (week 1) and at the end of the profilaxis treatment phase, up to 6 weeks
| Intervention | participants (Number) |
|---|---|
| Amphotericin B (ABELCET®) | 3 |
Percentage of deaths related to Invasive Pulmonary Aspergillosis during the prophylactic treatment period with Abelcet® in paediatric patients with Acute Leukaemia undergoing intensive chemotherapy. (NCT01615809)
Timeframe: at the Baseline visit (week 1) and at the end of the profilaxis treatment phase, up to 6 weeks
| Intervention | percentage of deaths (Number) |
|---|---|
| Amphotericin B (ABELCET®) | 0 |
is assessed by the proportion of patients who discontinue prophylactic treatment with Abelcet® due to an adverse event that is related or not to the study drug or for intolerability to it. The last week of treatment will have a different calendar for each participant, depending on the number of cicles needed by each patient (it has been anticipated up to 5 cicles of 2-6 weeks each). (NCT01615809)
Timeframe: at the Baseline visit (week 1) and during the Last week of treatment, up to 6 weeks
| Intervention | participants (Number) |
|---|---|
| Amphotericin B (ABELCET®) | 0 |
4 reviews available for fluconazole and Leukemia
| Article | Year |
|---|---|
[Prophylaxis and treatment for invasive fungal infection: update].
Topics: Fluconazole; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Mycoses; Practice Guidelines | 2013 |
Candida tropicalis infections in children with leukemia.
Topics: Abscess; Adolescent; Amphotericin B; Candida; Candidiasis; Cerebrospinal Fluid; Child; Child, Presch | 1993 |
Therapy for fungal infections in leukemia.
Topics: Amphotericin B; Aspergillosis; Azoles; Candidiasis; Fluconazole; Humans; Immunotherapy; Leukemia; My | 2001 |
Antifungal treatment strategy in leukemia patients.
Topics: Amphotericin B; Antifungal Agents; Drug Therapy, Combination; Fluconazole; Flucytosine; Humans; Itra | 1992 |
20 trials available for fluconazole and Leukemia
| Article | Year |
|---|---|
Benefits of risk-adapted and mould-specific antifungal prophylaxis in childhood leukaemia.
Topics: Amphotericin B; Aspergillosis; Aspergillus; Child; Child, Preschool; Female; Fluconazole; Humans; Le | 2020 |
A prospective randomized trial of itraconazole vs fluconazole for the prevention of fungal infections in patients with acute leukemia and hematopoietic stem cell transplant recipients.
Topics: Acute Disease; Adolescent; Adult; Aged; Antifungal Agents; Aspergillosis; Drug Administration Schedu | 2006 |
Effect of prophylactic fluconazole on the frequency of fungal infections, amphotericin B use, and health care costs in patients undergoing intensive chemotherapy for hematologic neoplasias.
Topics: Adult; Amphotericin B; Antibiotic Prophylaxis; Antifungal Agents; Aspergillosis; Bacteremia; Candidi | 1995 |
Systemic amphotericin B versus fluconazole in the management of antibiotic resistant neutropenic fever--preliminary observations from a pilot, exploratory study.
Topics: Adult; Amphotericin B; Aspergillosis, Allergic Bronchopulmonary; Bone Marrow Transplantation; Female | 1995 |
[A comparative clinical study on flucytosine alone and in combination with fluconazole in hematological malignancies: a multicenter study using the envelope method].
Topics: Adult; Aged; Aged, 80 and over; Drug Therapy, Combination; Female; Fluconazole; Flucytosine; Glucans | 1994 |
An open study on the safety and efficacy of fluconazole in the treatment of disseminated Candida infections in patients treated for hematological malignancy.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aspergillosis; Aspergillus fumigatus; Candidiasis; Fe | 1995 |
Administration of the antimycotic agents fluconazole and itraconazole to leukaemia patients: a comparative pharmacokinetic study.
Topics: Adolescent; Adult; Antifungal Agents; Chromatography, High Pressure Liquid; Drug Interactions; Femal | 1994 |
[Empiric therapy with fluconazole in granulocytopenic patients with carcinoma or leukemia].
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antineoplastic Agents; Bacterial Infections; | 1994 |
Antifungal prophylaxis during remission induction therapy for acute leukemia fluconazole versus intravenous amphotericin B.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Amphotericin B; Blast Crisis; Female; Flu | 1994 |
Controlled study of fluconazole in the prevention of fungal infections in neutropenic patients with haematological malignancies and bone marrow transplant recipients.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Clotrimazole; Female; Fluconazole; Humans; Leukemia; | 1994 |
Preventing fungal infection in neutropenic patients with acute leukemia: fluconazole compared with oral amphotericin B.
Topics: Acute Disease; Administration, Oral; Administration, Topical; Adolescent; Adult; Aged; Amphotericin | 1994 |
The effect of fluconazole prophylaxis on fungal colonization in neutropenic cancer patients. Bone Marrow Transplantation Team.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Candida; Candidiasis; Colony Count, Microbial; Doubl | 1994 |
[A clinical study of fluconazole in the treatment of systemic mycosis associated with immunocompromised children].
Topics: Candidiasis; Child; Female; Fluconazole; Fungemia; Humans; Immune Tolerance; Immunologic Deficiency | 1994 |
[Clinical study of fluconazole for systemic fungal infections with hematological disorders].
Topics: Adolescent; Adult; Aged; Child; Female; Fluconazole; Humans; Leukemia; Lymphoma; Male; Middle Aged; | 1993 |
Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Double-Blind Method; Female; Fluconazole; | 1993 |
[The empirical antibiotic therapy of patients with acute leukemias: the results of a multicenter study].
Topics: Acute Disease; Adult; Ampicillin; Anti-Bacterial Agents; Cefoperazone; Cephalosporins; Drug Therapy, | 1998 |
A double-blind comparison of fluconazole and nystatin in the prevention of candidiasis in patients with leukaemia. Antifungal Prophylaxis Study Group.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antifungal Agents; | 1999 |
A randomized study to compare oral fluconazole to amphotericin B in the prevention of fungal infections in patients with acute leukaemia.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Aged; Agranulocytosis; Amphotericin B; Femal | 1991 |
[Comparison of oral fluconazole and amphotericin B prophylaxis against fungal infections in the neutropenic phase of patients treated with antileukemic agents].
Topics: Administration, Oral; Adolescent; Adult; Aged; Amphotericin B; Antineoplastic Agents; Female; Flucon | 1990 |
Prevention of gram-positive and Candida albicans infections using teicoplanin and fluconazole: a randomized study in neutropenic children.
Topics: Acute Disease; Adolescent; Anti-Bacterial Agents; Bacterial Infections; Candidiasis; Child; Child, P | 1990 |
34 other studies available for fluconazole and Leukemia
| Article | Year |
|---|---|
Initial fluconazole prophylaxis may not be required in adults with acute leukemia or myelodysplastic/myeloproliferative disorders after reduced intensity conditioning peripheral blood stem cell allogeneic transplantation.
Topics: Acute Disease; Adult; Aged; Chemoprevention; Female; Fluconazole; Humans; Leukemia; Male; Middle Age | 2015 |
Candida tropicalis bloodstream infection: Incidence, risk factors and outcome in a population-based surveillance.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antifungal Agents; Candida tropicalis; Candidemia; Cent | 2015 |
Allogeneic hematopoietic cell transplantation without fluconazole and fluoroquinolone prophylaxis.
Topics: Adult; Aged; Female; Fluconazole; Fluoroquinolones; Hematopoietic Stem Cell Transplantation; Humans; | 2016 |
Invasive fungal infections in pediatric leukemia patients receiving fluconazole prophylaxis.
Topics: Adolescent; Antifungal Agents; Antineoplastic Agents; Child; Child, Preschool; Female; Fluconazole; | 2009 |
An atypical, pigment-producing Metschnikowia strain from a leukaemia patient.
Topics: Amphotericin B; Antifungal Agents; Base Sequence; DNA, Fungal; DNA, Ribosomal; Fluconazole; Humans; | 2013 |
Breakthrough fungemia caused by azole-resistant Candida albicans in neutropenic patients with acute leukemia.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Amphotericin B; Antifungal Agents; Antineoplastic Age | 2003 |
How to improve the design of trials of antifungal prophylaxis among neutropenic adults with acute leukemia.
Topics: Acute Disease; Adult; Antifungal Agents; Clinical Trials as Topic; Fluconazole; Humans; Itraconazole | 2004 |
Necrotic ulcer on the thumb of a teenager with leukemia.
Topics: Adolescent; Amphotericin B; Antifungal Agents; Aspergillosis; Aspergillus flavus; Dermatomycoses; Fa | 2005 |
Candida glabrata fungemia in transplant patients receiving voriconazole after fluconazole.
Topics: Adolescent; Adult; Candida glabrata; Female; Fluconazole; Fungemia; Humans; Leukemia; Male; Microbia | 2005 |
Role of prospective screening of blood for invasive aspergillosis by polymerase chain reaction in febrile neutropenic recipients of haematopoietic stem cell transplants and patients with acute leukaemia.
Topics: Acute Disease; Adolescent; Adult; Antifungal Agents; Aspergillosis; Aspergillus; DNA, Fungal; Female | 2006 |
Zygomycosis in the immunocompromised patient: a case report.
Topics: Absidia; Acute Disease; Aerosols; Amphotericin B; Amsacrine; Antibiotic Prophylaxis; Antifungal Agen | 2006 |
Fluconazole and itraconazole susceptibilities of Candida spp. isolated from oropharyngeal specimens and blood cultures of paediatric haematology/oncology patients.
Topics: Candida; Candidiasis; Fluconazole; Fungemia; Itraconazole; Leukemia; Microbial Sensitivity Tests; Or | 2006 |
Drug-drug interactions with systemic antifungals in clinical practice.
Topics: Adult; Aged; Amphotericin B; Antifungal Agents; Creatinine; Cyclosporine; Drug Interactions; Female; | 2007 |
Effect of fluconazole prophylaxis on the incidence of invasive candida infections and bacteraemias in patients with acute leukaemia.
Topics: Adult; Bacteremia; Candidiasis; Fluconazole; Humans; Leukemia; Retrospective Studies | 2008 |
Invasive infection due to Candida krusei in immunocompromised patients not treated with fluconazole.
Topics: Abdominal Injuries; Adult; Aged; Breast Neoplasms; Candidiasis; Child; Child, Preschool; Female; Flu | 1995 |
Risk factors for hepatosplenic abscesses in patients with acute leukemia receiving empiric azole treatment.
Topics: Abscess; Acute Disease; Adolescent; Adult; Aged; Candidiasis; Female; Fever; Fluconazole; Humans; Le | 1994 |
Notable clinical changes of hepatosplenic abscesses in febrile neutropenic patients receiving empiric antifungal treatment with azoles.
Topics: Abscess; Antifungal Agents; Candidiasis; Fever; Fluconazole; Humans; Leukemia; Liver Abscess; Lympho | 1994 |
Prevention of invasive fungal infection during chemotherapy-induced neutropenia in patients with acute leukemia.
Topics: Acute Disease; Administration, Inhalation; Administration, Oral; Adolescent; Adult; Aged; Amphoteric | 1994 |
[The use of diflucan in myelotoxic agranulocytosis].
Topics: Acute Disease; Adult; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; | 1993 |
Fluconazole prophylaxis in patients with leukemia.
Topics: Acute Disease; Candidiasis; Fluconazole; Humans; Leukemia | 1993 |
Fluconazole prophylaxis in patients with leukemia.
Topics: Acute Disease; Candidiasis; Fluconazole; Humans; Leukemia | 1993 |
Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients.
Topics: Amphotericin B; Bacterial Infections; Bone Marrow Transplantation; Candida; Candidiasis; Fluconazole | 1993 |
[Efficacy of fluconazole on systemic mycosis associated with hematologic malignancies and a study on diagnostic value of plasma beta-D-glucan levels].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; beta-Glucans; Biomarkers; Drug Evaluation; Female; Fluco | 1993 |
Breakthrough candidemia during antifungal treatment with fluconazole in patients with hematologic malignancies.
Topics: Candida; Candidiasis; Catheterization, Central Venous; Disease Susceptibility; Drug Resistance, Micr | 1996 |
[Clinical efficacy of fluconazole against fungal infections in hematological diseases].
Topics: Adult; Antifungal Agents; Female; Fluconazole; Fungemia; Humans; Injections, Intravenous; Leukemia; | 1996 |
[A clinical evaluation of fluconazole in deep seated fungal infections associated with hematological disorders].
Topics: Aged; Aged, 80 and over; Antifungal Agents; Female; Fluconazole; Humans; Leukemia; Lymphoma; Male; M | 1996 |
Pharmacokinetics of oral fluconazole when used for prophylaxis in bone marrow transplant recipients.
Topics: Administration, Oral; Adolescent; Adult; Antifungal Agents; Bone Marrow Transplantation; Chromatogra | 1997 |
Antifungal susceptibility of Aspergillus species isolated from invasive oral infection in neutropenic patients with hematologic malignancies.
Topics: Adult; Aged; Amphotericin B; Antifungal Agents; Antineoplastic Agents; Aspergillosis; Aspergillus; D | 1999 |
Extended routine polymerase chain reaction surveillance and pre-emptive antiviral therapy for cytomegalovirus after allogeneic transplantation.
Topics: Acyclovir; Adolescent; Adult; Antifungal Agents; Antiviral Agents; Bone Marrow Transplantation; Cycl | 2000 |
Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole.
Topics: Adult; Amphotericin B; Bone Marrow Transplantation; Candidiasis; Drug Therapy, Combination; Fluconaz | 1991 |
Hepatosplenic candidiasis: successful treatment with fluconazole.
Topics: Acute Disease; Adolescent; Adult; Amphotericin B; Candidiasis; Child; Child, Preschool; Fluconazole; | 1991 |
The effectiveness of a preventive regimen on the periodontal health of patients undergoing chemotherapy for leukemia and lymphoma.
Topics: Acyclovir; Amphotericin B; Ceftazidime; Chlorhexidine; Dental Plaque Index; Fluconazole; Humans; Imm | 1991 |
[Clinical evaluation of fluconazole in the case of deep mycosis associated with leukemia].
Topics: Acute Disease; Adolescent; Adult; Aged; Antifungal Agents; Candidiasis; Drug Evaluation; Drug Tolera | 1989 |
[A clinical evaluation of injectable fluconazole in the treatment of deep mycosis associated with hematological malignancy].
Topics: Acute Disease; Adolescent; Adult; Aged; Antifungal Agents; Candida; Candidiasis; Drug Evaluation; Dr | 1989 |